Zydus Takeda Healthcare Private Limited, a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Company Limited, recently celebrated the 25th anniversary of the Vashi manufacturing plant in India.
Looking to the future, Zydus Takeda aims to elevate the site’s role within Takeda's strategic network. Key initiatives include expanding the product portfolio with new active pharmaceutical ingredients (APIs) and key starting materials (KSMs), enhancing kilo lab facilities, transitioning to renewable energy to support Takeda’s net-zero emissions goal, investing in digital automation technologies to improve efficiency and reducing waste.
Additionally, the focus is on developing new supply chain strategies, strengthening global collaboration, driving employee engagement through continuous learning, and advancing initiatives focused on health and environmental sustainability.
Over the past 25 years, the manufacturing site at Vashi has emerged as a supplier of APIs and intermediates for Takeda’s markets in Europe, Japan, Brazil, and Korea. As a 100% export-oriented unit, it has consistently put safety and quality first. Reflecting on its journey, the site successfully executed capacity enhancements and multiple tech transfers for key Takeda small molecule products, and maintained competitiveness, making it an important manufacturing site within Takeda’s network.
